Refine By Content Type
Refine By Year
With a novel topical agent (tapinarof) in development for psoriasis, Dermavant is rooted in dermatology with an eye toward aesthetics. Dermavant CEO...
Steve Dayan, MD
BTL has launched multiple devices in the US, including Emsculpt, for building muscle. Scott Mills, Vice President of Sales at BTL, discusses the...
Steve Dayan, MD; and Scott Mills
With recent investment in the company and the launch of a new technology, Beautifill, Alma Lasers looks to expand its role in the US aesthetics...
With innovations in the RF micro needling experience and topical PRP treatments, Aesthetics Biomedical is building a name in the aesthetics space. CEO...
MaryAnn Guerra, Steven Dayan, MD
A new technology that mechanically creates microwounds in the skin may address sagging and even fat deposits. Recros Medica CEO Tom Albright discusses...
Steven Dayan, MD, Tom Albright
Stratpharma offers solutions to treat and prevent scarring. Learn about the company and how it plans to grow in the aesthetics space. Executive Vice...
James Kone, Steven Dayan, MD
Evolus may be one of the buzziest companies in the aesthetics space. CEO David Moatazedi talks to host Steven Dayan, MD about the company's past,...
With the launch of Eskata and the acquisition of Rhofade, Aclaris Therapeutics is making a mark in the aesthetics and dermatology markets. CEO and...
Neal Walker, DO, Steven Dayan, MD
The hair market is large and growing. Nutrafol is an oral supplement intended to support hair health. Roland Peralta, Co-founder and President of...
Roland Peralta, Steven Dayan, MD
With its SkinPen Device, Bellus Medical is seeking to establish a new class of FDA-regulated, non-thermal devices. Joe Proctor, CEO of Bellus Medical,...
Joe Proctor, Steven Dayan, MD
As its brands experience continued growth, Merz Aesthetics is poised for additional success in the US aesthetics space, says Bob Rhatigan, CEO. In an...
Bob Rhatigan, Steven Dayan, MD
With a recent cash infusion, Thermi is focused on its core products and clients. Learn about It's research goals and more as Vlad Paul-Blanc speaks...
Steven Dayan, MD, Vlad Paul-Blanc
With positive data now available from pivotal phase 3 SAKURA 1 and 2 trials, Revance is eyeing the potential opportunity to bring DaxibotulinumtoxinA...
Dan Browne, Steven Dayan, MD